AVR-110 also reduced AR-target gene expression in enzalutamide-resistant tumor models, targeted wild type AR (WT-AR), and amplified AR with T878A, H875Y, F877L, and M895V mutations, but not in tumors with L702H or AR-V7 mutations. The gene discussed is AR; the disease is neoplasm.